Short Interest in Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Increases By 3,625.0%

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) was the target of a large increase in short interest in May. As of May 15th, there was short interest totaling 596 shares, an increase of 3,625.0% from the April 30th total of 16 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 6,288 shares, the days-to-cover ratio is presently 0.1 days.

Analysts Set New Price Targets

Several analysts have commented on AAPG shares. China Intl Cap upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th. Deutsche Bank Aktiengesellschaft started coverage on shares of Ascentage Pharma Group International in a research note on Friday, April 24th. They issued a “buy” rating and a $40.00 price target on the stock. Finally, BTIG Research reiterated a “buy” rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Monday, April 13th. Two investment analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $46.67.

Hedge Funds Weigh In On Ascentage Pharma Group International

A number of hedge funds have recently added to or reduced their stakes in AAPG. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Ascentage Pharma Group International in the 3rd quarter worth approximately $96,000. ABC Arbitrage SA purchased a new stake in shares of Ascentage Pharma Group International in the 3rd quarter worth approximately $204,000. Citadel Advisors LLC purchased a new stake in shares of Ascentage Pharma Group International in the 3rd quarter worth approximately $383,000. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International in the 2nd quarter worth approximately $391,000. Finally, XY Capital Ltd lifted its position in shares of Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares during the period.

Ascentage Pharma Group International Stock Up 2.2%

NASDAQ:AAPG traded up $0.44 during mid-day trading on Wednesday, hitting $20.57. 10,113 shares of the stock traded hands, compared to its average volume of 6,116. Ascentage Pharma Group International has a 52 week low of $18.56 and a 52 week high of $48.45. The firm’s 50 day moving average is $23.23 and its two-hundred day moving average is $25.90. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its earnings results on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The business had revenue of $24.72 million for the quarter. As a group, equities research analysts predict that Ascentage Pharma Group International will post -1.09 earnings per share for the current fiscal year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.